VivoSim Labs, Inc. (VIVS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.83 |
| Open | 1.49 |
| Day High | 1.57 |
| Day Low | 0.91 |
| 52-Week High | 5.3 |
| 52-Week Low | 0.78 |
| Volume | 93.77M |
| Average Volume | 92,604 |
| Market Cap | 2.5M |
| PE | -0.14 |
| EPS | -6.63 |
| Moving Average 50 Days | 1.19 |
| Moving Average 200 Days | 1.88 |
| Change | 0.13 |
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
GlobeNewswire Inc.
Mar 03, 2026 1:05 PM GMT
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with biopharma innovators seeking human-relevant live
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
GlobeNewswire Inc.
Feb 11, 2026 1:05 PM GMT
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effectsSAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Compa
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
GlobeNewswire Inc.
Jan 29, 2026 9:05 PM GMT
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: V